The New Old Age: In Flu Season,Use a Mask. But Which One?

Face masks help prevent people from getting the flu. But how much protection do they provide?

You might think the answer to this question would be well established. It’s not.

In fact, there is considerable uncertainty over how well face masks guard against influenza when people use them outside of hospitals and other health care settings. This has been a topic of discussion and debate in infectious disease circles since the 2009 H1N1 flu pandemic, also known as swine flu.

As the government noted in a document that provides guidance on the issue, “Very little information is available about the effectiveness of facemasks and respirators in controlling the spread of pandemic influenza in community settings.” This is also true of seasonal influenza — the kind that strikes every winter and that we are experiencing now, experts said.

Let’s jump to the bottom line for older people and caregivers before getting into the details. If someone is ill with the flu, coughing and sneezing and living with others, say an older spouse who is a bit frail, the United States Centers for Disease Control and Prevention recommends the use of a face mask “if available and tolerable” or a tissue to cover the nose and mouth.

If you are healthy and serving as a caregiver for someone who has the flu — say, an older person who is ill and at home — the C.D.C. recommends using a face mask or a respirator. (I’ll explain the difference between those items in just a bit.) But if you are a household member who is not in close contact with the sick person, keep at a distance and there is no need to use a face mask or respirator, the C.D.C. advises.

The recommendations are included in another document related to pandemic influenza — a flu caused by a new virus that circulates widely and ends up going global because people lack immunity. That is not a threat this year, but the H3N2 virus that is circulating widely is hitting many older adults especially hard. So the precautions are a good idea, even outside a pandemic situation, said Dr. Ed Septimus, a spokesman for the Infectious Diseases Society of America.

The key idea here is exposure, Dr. Septimus said. If you are a caregiver and intimately exposed to someone who is coughing, sneezing and has the flu, wearing a mask probably makes sense — as it does if you are the person with the flu doing the coughing and sneezing and a caregiver is nearby.

But the scientific evidence about how influenza is transmitted is not as strong as experts would like, said Dr. Carolyn Bridges, associate director of adult immunization at the C.D.C. It is generally accepted that the flu virus is transmitted through direct contact — when someone who is ill touches his or her nose and then a glass that he or she hands to someone else, for instance — and through large droplets that go flying through the air when a person coughs or sneezes. What is not known is the extent to which tiny aerosol particles are implicated in transmission.

Evidence suggests that these tiny particles may play a more important part than previously suspected. For example, a November 2010 study in the journal PLoS One found that 81 percent of flu patients sent viral material through air expelled by coughs, and 65 percent of the virus consisted of small particles that can be inhaled and lodge deeper in the lungs than large droplets.

That is a relevant finding when it comes to masks, which cover much of the face below the eyes but not tightly, letting air in through gaps around the nose and mouth. As the C.D.C.’s advisory noted, “Facemasks help stop droplets from being spread by the person wearing them. They also keep splashes or sprays from reaching the mouth and nose of the person wearing them. They are not designed to protect against breathing in the very small particle aerosols that may contain viruses.”

In other words, you will get some protection, but it is not clear how much. In most circumstances, “if you’re caring for a family member with influenza, I think a surgical mask is perfectly adequate,” said Dr. Carol McLay, an infection control consultant based in Lexington, Ky.

By contrast, respirators fit tightly over someone’s face and are made of materials that filter out small particles that carry the influenza virus. They are recommended for health care workers who are in intimate contact with patients and who have to perform activities like suctioning their lungs. So-called N95 respirators block at least 95 percent of small particles in tests, if properly fitted.

Training in how to use respirators is mandated in hospitals, but no such requirement applies outside, and consumers frequently put them on improperly. One study of respirator use in New Orleans after Hurricane Katrina, when mold was a problem, found that only 24 percent of users put them on the right way. Also, it can be hard to breathe when respirators are used, and this can affect people’s willingness to use them as recommended.

Unfortunately, research about the relative effectiveness of masks and respirators is not robust, and there is no guidance backed by scientific evidence available for consumers, Dr. Bridges said. Nor is there any clear way of assessing the relative merits of various products being sold to the public, which differ in design and materials used.

“Honestly, some of the ones I’ve seen are almost like a paper towel with straps,” Dr. McLay said. Her advice: go with name-brand items used by your local hospital.

Meanwhile, it is worth repeating: The single most important thing that older people and caregivers can do to prevent the flu is to be vaccinated, Dr. Bridges said. “It’s the best tool we have,” she said, noting that preventing flu also involves vigilant hand washing, using tissues or arms to block sneezing, and staying home when ill so people do not transmit the virus. And it is by no means too late to get a shot, whose cost Medicare will cover for older adults.

Read More..

Conversation: A Founder of the Soap Maker Method Discusses Its Sale





For Eric Ryan and Adam Lowry, the quest began in 2001 in what they call a “dirty little flat” in San Francisco, where the two childhood buddies from Detroit first plotted to disrupt the all-but-impenetrable cleaning products industry long dominated by giants like SC Johnson and Procter & Gamble.




They started by mixing soap formulas in beer pitchers labeled “Do Not Drink” and wound up creating Method, an irreverent, design-driven, environmentally minded company that outsourced manufacturing. The company grew to $34 million in revenue and 39 employees in 2005, and more than $100 million and 100 employees in 2012. Those numbers remain modest compared to those of Big Soap, but a walk down the cleaning aisle in almost any supermarket reveals not just Method’s reach (Ginger Yuzu dish soap, Pink Grapefruit hand wash) but its impact on competitors (Clorox Green Works).


“We showed up at the party with a very different proposition,” Mr. Ryan said. “We’re superproud that we’ve had an influence.”


That influence will continue, Mr. Ryan and Mr. Lowry suggest, even though Method was acquired for an undisclosed price in September by the Belgian company Ecover, creating what they claim is now the largest green cleaning company in the world, with revenue “north of $200 million.”


In a conversation that has been edited and condensed, we recently asked Mr. Ryan why he and Mr. Lowry chose to sell, how they identified the right suitor, and what will happen to the Method brand.


Q. Was selling the company always a primary goal?


A. When we started the company, we knew we had two choices. One was to grow organically, which a lot of businesses do, and you control the business and grow slowly and steadily. We fundamentally believed that we would not have success in this competitive space unless we went after it fast and aggressively. So we had to take outside capital. And when we took that outside capital — at some point, you have to give it back with a return.


Q. You make soap, you sell it, you make more soap, you sell more of it. Why couldn’t you grow without being acquired?


A. Two primary reasons. One is just economies of scale. In the early years, we lost money on every product we sold. We were competing against companies that not only have a 100-year head start but have just built incredible efficiencies. They own their own plants. When you walk in a grocery store and that bottle of dish soap sells for $1.99, we could not make it for $1.99 in the beginning. We needed capital to accelerate growth, to get our volume to a place where the business would be profitable. Two is that the cost of doing business in the mass channel is really expensive. When you sell in a grocery store, you have to pay an upfront fee called slotting charges. And that takes a fair amount of capital. So growing organically is possible, but it’s really, really tough.


Q. You’ve built a brand that seems to resonate with consumers. Are you concerned about their reaction to the sale?


A. It was something that was heavy in our minds for a lot of years. The typical script for a socially driven company like ours is you get acquired by a major strategic. So look at Honest Tea, acquired by Coke. Kashi by Kellogg. Burt’s Bees by Clorox. Even Mrs. Meyer’s, in our space, by SC Johnson. I always justified it by saying, “Well, if that happens, it’ll give us the chance to work from a bigger, global stage, and we’ll try to change those companies from the inside out.” And once we did this deal, I was just so thankful we never had to go down that path. We recognized we had a partner at the table with identical mission statements, identical values and a real long-term commitment. It was just an opportunity too good to pass up.


Q. Did you say no to other offers because you didn’t see that cultural fit?


A. We can’t name names, but we did have, over the years, conversations with those usual suspects. And the movie looked pretty similar — full integration, we go from being a company to being an operating unit within a larger organization. The culture, the team, “the Method Method” that we spent the last 10 years building would have been nonexistent within 12 months.


Q. Will the Method brand continue to exist?


A. Very much so. We’ll be building our own plant in North America. We’re turning on TV advertising for the first time in our history. We’re expanding more aggressively in Europe and Asia than we would have done otherwise. We’re creating a company with a long-term focus on the future. When you’re private equity-backed, it’s a much more short-term focus in how you invest and build the organization. The big thing that’s changing now, we’re a house of brands, which is Method and Ecover. And we have to set up a business where they coexist in a way that they don’t cannibalize each other and reach a broader audience collectively.


Q. Obviously, you’re in the honeymoon phase. How do you protect against something going wrong?


A. At the end of the day, it’s like a marriage — there is a leap of faith. And the way that you can protect yourself the most is just really trusting your instincts of who you’re jumping in bed with. It’s just like a job interview or any other relationship. If you’re getting to a point where you’re having to lean on a lot of legalities or other ways to try to protect yourself, it’s probably not the right relationship. It just comes back again to, are these people you trust, who share the same vision?


Q. While this was developing, how open were you with your employees?


A. You just can’t talk openly. It can do damage to the deal, but also, it’s a roller coaster, and you don’t want everyone riding the roller coaster with you. It’s incredibly distracting. There was a very small group that was in the know, and those were only the ones that were needed for due diligence. People knew we were looking and we were upfront about that, but they didn’t know to what extent, because we didn’t know to what extent. So when we did the announcement, there was initial shock, but over all it went well. And then for the next week, it was really challenging because what happened — what we were completely blindsided by — was how many people in their careers had been through a bad M.& A. transaction. There were a lot of bad movies that started being replayed. What I told everybody was, “Look, I’ve never been through a bad merger in my life, and I’m not about to start now.”


Q. Things have been tough in Europe. Any concerns about partnering with a European company and expanding there?


A. I like the idea of investing when something is at its lowest. [Laughs.] No, we have not had too many concerns about it. This business is firing on all cylinders. I was definitely, in the back of my head, concerned that things would get derailed by the European crisis, but who we’re dealing with is very long-term focused and they’re also very globally minded. Europe is a big part of their business, but they’re also expanding aggressively in Asia — we are as well — and North America.


Q. And everyone needs soap.


A. And everybody needs soap. It’s a dirty world out there.


Read More..

Deadly Explosions Hit Aleppo University





A series of deadly explosions struck the Aleppo University campus in Syria on Tuesday, antigovernment activists and Syrian state television reported, in what appeared to be a major expansion of the violent struggle for control of the largest city in the nearly two-year-old Syrian conflict. Each side blamed the other for the blasts.




Antigovernment activists also reported that violence convulsed some suburbs of Damascus, the capital, where members of the insurgent Free Syrian Army were engaged in combat with government forces in the Ain Tarma and Zamalka neighborhoods. The fighting erupted after a campaign of Syrian Air Force attacks over the past few days apparently aimed at expunging insurgents from strategic areas. The Syrian Observatory for Human Rights, an antigovernment group based in Britain with a network of contacts in Syria, said at least 15 people were killed and dozens wounded in the explosions at Aleppo University, which was in a government-controlled part of Aleppo and had been conducting classes despite the mayhem and deprivation that have ravaged other parts of the city.


Aleppo, in northern Syria, has essentially been under siege since July, with insurgents and government forces in a stalemate. The city, which was once the commercial epicenter of Syria, has been struck by numerous shellings, bombings and airstrikes, but the university area had been largely spared until Tuesday.


Antigovernment activists said the university dormitories, which had been housing both students and civilians displaced by fighting elsewhere, were hit by one missile fired by Syrian military forces. They said buildings housing the architecture and humanities departments were also hit by missiles fired by the military.


Syria’s state-run SANA news service did not specify the number of casualties but said the explosions came on the first day of exams. SANA attributed the death and destruction to at least two rockets fired by what it called terrorists, the government’s blanket description for the armed insurgency against President Bashar al-Assad.


Photographs and video uploaded on the Internet by antigovernment groups showed extensive destruction of dormitory buildings, the hulks of several burned vehicles and bodies on the ground.


The United Nations has estimated that more than 60,000 people have been killed in Syria since the uprising against Mr. Assad began in March 2011.


Mr. Assad appeared to further distance himself on Monday from any thought of relinquishing power via a BBC interview with his deputy foreign minister, Faisal Muqdad. Mr. Muqdad suggested that Mr. Assad would run for re-election next year when his term expires. “We are opening the way for democracy, or deeper democracy,” he said. “In a democracy you don’t tell somebody not to run.”


Groups opposed to Mr. Assad have said they will not even consider political dialogue to resolve the conflict unless Mr. Assad resigns or is removed from power first. The special peace envoy from the United Nations and the Arab League, Lakhdar Brahimi, has urged Mr. Assad to step down and said he cannot be part of any transitional government. The Syrian government has accused Mr. Brahimi of bias toward the insurgency.


With diplomacy still deadlocked, more than 50 member states in the United Nations submitted an unusual written appeal to the Security Council on Monday to at least request an investigation by the International Criminal Court into possible war crimes and atrocities committed in Syria, by both the loyalist and the insurgent sides.


But whatever chance of such a move appeared to be ended on Tuesday by Russia, the biggest foreign defender of the Syrian government, which has vetoed three Security Council proposals on Syrian intervention since the conflict began.


“We consider this initiative ill-timed and counterproductive if we are to achieve the current priority goal — an immediate end to bloodshed in Syria,” Russia’s Foreign Ministry said in a statement. “We are convinced that speculation about international criminal prosecution and the search for guilty parties will only serve to keep the opposing sides in hard-line positions and complicate the search for a path of political-diplomatic settlement of the Syrian conflict.”


Rick Gladstone reported from New York, and Hwaida Saad from Beirut, Lebanon. Ellen Barry contributed reporting from Moscow.



Read More..

SAP earnings fall short of expectations


FRANKFURT (Reuters) - Quarterly earnings from SAP AG fell short of expectations on Tuesday, showing the German business software maker failed to keep up with arch-rival Oracle Corp and sending its shares sharply lower.


SAP's results, released more than a week before they had been scheduled, showed group revenue rose 12 percent to 5.06 billion euros ($6.8 billion), below an average analyst forecast of 5.17 billion, according to Reuters data.


Operating profit rose more slowly than revenue, gaining 10 percent to 1.96 billion euros, resulting in SAP's operating margin narrowing by 0.8 percentage points to 38.8 percent in the three months through December.


The figures contrasted with those of Oracle, the world's No. 3 software maker and SAP's biggest competitor, which last month forecast strong sales for 2013 after posting a 17 percent jump in quarterly software revenue.


SAP shares were down 3.8 percent and were the biggest decliners in a 2 percent weaker sector index by 1500 GMT. The stock fell as low as 57.77 euros, its lowest in two months.


"Especially after their main competitor Oracle managed to beat estimates last month, many had hoped that SAP would follow suit," said Markus Huber, head of German trading at ETX Capital.


"Even by missing estimates by a very small margin, and despite having had an overall excellent 2012, investors are venting their disappointment by dumping the stock heavily," Huber added.


CLOUD BUSINESSES


SAP said its operating profit was affected by investments in web-based software products, also known as "cloud" businesses.


The Walldorf, southern Germany-based company, along with peers such as IBM and Oracle, are betting on faster-growing, web-based software products, which are less vulnerable to the economic downturn as there are no upfront costs for program licenses, dedicated hardware or installation.


SAP last year splashed out $7.7 billion to buy internet-based computing companies Ariba and SuccessFactors.


The web-based services garnered just 342 million euros in 2012 revenues, a fraction of the total 16.3 billion.


With a market capitalization of $100 billion, SAP is the second-most valuable company in the German blue chip index behind Volkswagen, which is worth $105 billion, according to Reuters data.


SAP is due to publish full financial results and a full-year outlook on January 23. Some analysts fear the 2013 outlook could also disappoint.


"Guidance could be slightly below current consensus and expectations may be revised lower," Barclays analyst Gerardus Vos said in a note.


SAP's full-year operating profit at constant currencies reached 5.02 billion euros, missing its own guidance for at least 5.05 billion euros.


($1 = 0.7482 euros)


(Additional reporting by Maria Sheahan; Editing by David Holmes)



Read More..

Not guilty plea entered for Lohan on misdemeanors


LOS ANGELES (AP) — Lindsay Lohan's attorney has entered a not guilty plea for the actress to three misdemeanor charges filed over a June accident in which her sports car slammed into a dump truck.


Attorney Shawn Holley entered the plea during a brief hearing Tuesday in Los Angeles.


The actress is accused of lying to police, reckless driving and obstructing police from performing their duties.


Police suspect she was driving her sports car when it slammed into the truck while she was on her way to the set of "Liz and Dick" in early June. Lohan told police she wasn't behind the wheel.


Lohan was on probation for a 2011 necklace theft case at the time, and could face up to 245 days in jail if a judge determines she violated her probation.


Read More..

Well: For DTaP Vaccine, Thigh May Be Better Injection Site Than Arm

Children are less likely to develop bad reactions to the DTaP vaccine, a routine immunization shot that protects against diphtheria, tetanus and pertussis, or whooping cough, if they get it in their thigh instead of in their arm, a new study shows.

The research looked at more than a million children who were given injections of the vaccine. In many cases it causes some degree of redness or swelling around the injection site, which typically goes away after a day. But in rare instances a child can develop a more pronounced reaction, like severe pain or a swollen limb, that may require medical attention.

In the new study, which was published in the journal Pediatrics, researchers found that children between the ages of 1 and 3 who were given the DTaP vaccine in their thigh instead of in their upper arm were around half as likely to have a local reaction that warranted a visit to a doctor, nurse or emergency room. Previous studies of children who received the vaccine between the ages of 4 and 6 found that they, too, had a lower likelihood of developing a local reaction requiring medical attention if they got the shot in their thigh instead of in their arm.

Why the vaccine would be less harsh on the thigh than the arm is not known for certain. But one possibility is simply that in children at that age, the thigh muscle is much larger than the deltoid, the muscle in the upper arm where shots are typically administered. If any inflammation ensues, it has more room to diffuse in the thigh, said Dr. Lisa A. Jackson, the lead author of the study and a senior investigator at the Group Health Research Institute in Seattle.

“In little kids the upper arm is very tiny,” she said. “You’re injecting the same volume of vaccine in the upper arm as in the thigh, which is a larger area. I think it’s just that it’s a larger muscle mass.”

The benefits, however, may not extend to other immunizations. The study, for example, also looked at shots for influenza and hepatitis A, and in those cases there was no meaningful difference between vaccinating in the arm or thigh for either toddlers or children ages 3 to 6.

In many cases, doctors choose where to administer a shot according to their own preference. But in the case of DTaP, at least, it makes more sense in general to give the shot in the thigh, Dr. Jackson said.

“Unless there’s a compelling reason not to, I would say veer toward giving the DTaP vaccine in the leg,” she said. “There’s less chance of a concerning reaction if you give it in the thigh versus the arm. So that should be the normal practice.”

Dr. Jackson stressed, however, that the absolute risk of a child having a reaction severe enough to warrant medical attention is still quite small, regardless of whether the shot is given in the arm or leg. The study found that it occurred in less than 1 percent of vaccinated children over all.

Read More..

Roche Hires Dr. John Reed to Lead Research Operations





The Swiss pharmaceutical giant Roche is turning to a prolific American academic scientist to revitalize its lagging research operations.




Dr. John C. Reed, the chief executive of the Sanford-Burnham Medical Research Institute in San Diego, will become head of Roche’s pharmaceutical research and early development group in April, the company announced Tuesday.


Dr. Reed, 54, has spent 21 years at Sanford-Burnham, formerly known as the Burnham Institute, the last 11 as chief executive.


During his tenure as chief executive, the institute grew rapidly, opened a new research site in Florida, and broadened its role from basic research to also doing drug discovery, in some cases in collaborations with pharmaceutical companies. It also received its largest donation ever, $50 million, from the credit card industry executive T. Denny Sanford, which led the institute to change its name.


Dr. Reed, 54, who holds both a medical degree and a Ph.D., is the author of more than 800 scientific papers, many dealing with why cancer cells do not commit suicide as errant cells are supposed to do. A triathlete, Dr. Reed used to get to his office around 3:30 a.m. each day, though now, with better computers, he works at home in the early hours.


“With his broad scientific and medical background, he is ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics,” Severin Schwan, the chief of Roche, said in a statement.


It is not unprecedented for drug companies to tap academic scientists to run research. Sanofi’s research and development is now run by Elias Zerhouni, the former director of the National Institutes of Health and professor at Johns Hopkins. Mark Fishman, a cardiologist at Harvard, was recruited to run research at Novartis, and Peter S. Kim, who heads research at Merck, was previously a biology professor at the Massachusetts Institute of Technology.


Dr. Reed, who has been on biotechnology company boards but never had a full-time corporate job, said in an interview that he was joining Roche to “have an opportunity to contribute on a larger stage, so to speak.”


At Roche he will oversee not only research but also early- and middle-stage clinical trials, something Sanford-Burnham does not do. He will supervise about 2,000 people with an annual budget in the billions, while Sanford-Burnham has about 1,200 people and a budget of around $175 million.


Dr. Reed, who will move to Basel, where Roche is based, said it was too early to discuss his agenda at Roche, other than to make its research more collaborative.


The operation Dr. Reed will run, called Pharma Research and Early Development, or pRED, does not include Genentech, the California biotechnology company that Roche fully acquired in 2009. In an effort to preserve the culture at Genentech, Roche left it autonomous, forming a group it calls gRED.


Recently, gRED has been eclipsing pRED. Roche’s three best-selling drugs, the cancer medicines Rituxan, Herceptin and Avastin, were developed at Genentech. So have some of its most attractive experimental drugs, including T-DM1, a breast cancer drug that could win regulatory approval early this year.


The organization Dr. Reed will run, by contrast, has had its share of problems in recent years. Several hundred researchers were cut in a corporate reorganization. And last year Roche discontinued development of a heart drug after it failed to work in a late-stage clinical trial.


The troubles contributed to Roche’s decision in June to shut its campus in Nutley, N.J., the birthplace of valium. At that time, Jean-Jacques Garaud, head of the Roche unit that Dr. Reed will run, left the company and was replaced on an interim basis by Mike Burgess. Roche said Tuesday that Mr. Burgess would now also leave the company.


Sanford-Burnham said that Dr. Kristiina Vuori, its president and head of its cancer center, would take over as chief executive on an interim basis. Dr. Vuori, who is originally from Finland, has worked closely with Dr. Reed.


M. Wainwright Fishburn Jr., the chairman of Sanford-Burnham, said it was “bittersweet” to see Dr. Reed leave. While the institute will lose a very successful leader, he said, the move could advance the institute’s efforts to get drug discovery work from pharmaceutical companies.


“We have one of our own in one of the most influential positions around,” he said.


This article has been revised to reflect the following correction:

Correction: January 15, 2013

A headline with an earlier version of this article misspelled the name of the drug maker. It is Roche, not Roches.



Read More..

New York Legislators Hope for Speedy Vote on Gun Laws





ALBANY — Gov. Andrew M. Cuomo and legislative leaders, nearing a deal on a broad package of changes to the state’s gun laws that would expand the state’s ban on assault weapons, were hoping to vote as soon as Monday on legislation prompted by last month’s mass shooting of a group of first graders in Newtown, Conn.




A vote early this week would make New York the first state to act in response to the shooting, and comes as President Obama on Monday reiterated his desire for a federal assault weapons ban.


The deal being negotiated in New York would not only expand the state’s ban on assault weapons, but would also reduce the legal capacity of gun magazines to 7 rounds, from 10. It would include new measures to keep guns away from the mentally ill, to increase penalties for gun crimes, and to require background checks for private gun sales. Some lawmakers also were seeking to expand Kendra’s Law, which empowers judges to order mentally ill patients to receive outpatient treatment.


“There’s a real push and hope to do something today, but right now we’re trying to make sure it’s technically sound,” said the Assembly majority leader, Joseph D. Morelle of Monroe County, the second highest-ranking official in the chamber. “If it goes into tomorrow, that’s a possibility. But there’s a sense that we’d like to do something.”


Senator Jeffrey D. Klein of the Bronx, the leader of an independent faction of Democrats that has allied with Senate Republicans, said: “I think when all is said and done, we’re going to pass a comprehensive gun bill today. And I think it’s important and this is an issue that shows we can work together, Democrats and Republicans.”


“Republicans, it’s very clear, wanted harsher criminal penalties for illegal guns, which is something I agree with, but on the other hand we’re also going to ban assault weapons and limit the number of rounds in a magazine,” he added. “So I think putting those two things together makes it a better bill.”


Senator Thomas W. Libous of Binghamton, the top deputy in the Republican caucus, called a gun control bill “inevitable,” adding, “It’s something that’s going to go forward.”


While the Senate has been pushing for tougher penalties for people who commit crimes with illegal guns, Mr. Libous said in an interview on WGDJ-AM that other aspects of the bill would make gun enthusiasts uneasy. He called it a “split decision.”


“I’m not going to sugarcoat it,” Mr. Libous said, adding, “There are a lot of things here that true Second Amendment believers are going to have some issues with.”


Officials familiar with the negotiations said that draft language had been developed by the governor’s office and legislative leaders, and that lawmakers planned to examine that draft language in closed-door meetings on Monday afternoon. A Cuomo administration official said no deal, tentative or otherwise, had been reached as of Monday morning.


The Legislature was scheduled to be in session only on Monday and Tuesday this week. For a vote to happen either of those days, Mr. Cuomo would need to waive the three-day waiting period for new legislation that is required in the State Constitution, something he has done in the past to allow for speedy votes on controversial legislative agreements.


The negotiations came amid a last-ditch lobbying effort by gun-rights groups and gun owners, many of them from upstate New York, who argued that passing new gun laws in a state that already has some of the toughest in the country would punish hunters and sportsmen but not cut down on violence. Mr. Cuomo has said his proposals would make New York’s gun laws the toughest in the country.


The final push to reach a deal came after weeks of fast-moving negotiations between Mr. Cuomo, a Democrat, and legislative leaders, who have long been divided over new gun control measures. The Democrat-controlled State Assembly has pressed for years to toughen New York’s laws, while the Republican majority in the Senate has resisted them.


Mr. Cuomo and other Democrats seized on the Dec. 14 Newtown massacre to argue that lawmakers needed not only to take action, but also to do so swiftly. The governor unveiled his plan for new gun laws only last week, in his State of the State address on Wednesday.


The negotiations over new gun laws is the first big test of a new power dynamic in Albany. The Assembly remains controlled by Democrats, as it has been for decades, and is strongly supportive of gun control. The Senate, which had been controlled by Republicans generally opposed to new gun control measures, is now being led by a coalition of Republicans and dissident Democrats; those Democrats are also supportive of new gun measures.


Read More..

Apple cuts orders for iPhone 5 parts on weak demand: Nikkei


(Reuters) - Apple Inc has cut orders for LCD screens and other parts for the iPhone 5 this quarter due to weak demand, the Nikkei reported on Monday, in a further sign the U.S. firm is losing ground to Asian smartphone rivals.


Shares of the Cupertino, California-based company fell more than 4 percent to $498.20 before the bell on Monday. They closed at $520.30 on Friday on the Nasdaq. The news also dragged shares of Apple suppliers such as Cirrus Logic Inc and Qualcomm Inc.


Apple has asked Japan Display Inc, Sharp Corp and South Korea's LG Display Co Ltd to roughly halve supplies of LCD panels from an initial plan for about 65 million screens in January-March, the Japanese daily said, citing people familiar with the situation, adding the U.S. firm also cut orders for other iPhone components.


The move, if confirmed, would tally with analysts saying that sales of the new iPhone 5, which was released in September, have not been as strong as anticipated.


Apple was not immediately available for comment outside regular U.S. business hours. No one at Sharp was immediately available to comment on Monday - a national holiday in Japan - and parts suppliers to Apple in Taiwan declined to comment.


Apple has lost ground in the $200 billion plus global smartphone market to South Korean rival Samsung Electronics and smaller Chinese rivals such as Huawei Technologies Co Ltd and ZTE Corp.


Jefferies analyst Peter Misek trimmed his iPhone shipment estimates for the January-March quarter on December 14, saying that the technology company had started cutting orders to suppliers to balance excess inventory.


Apple also cut its orders for memory chips for its new iPhone from its main supplier and competitor Samsung, Reuters reported in September, quoting sources with direct knowledge of the matter.


The company has been cutting back its orders from Samsung as it seeks to diversify its memory chip supply lines.


SAMSUNG OVERTAKES APPLE


Samsung said on Monday that global sales of its flagship Galaxy S smartphones had topped 100 million since the first model was launched in May 2010. The Galaxy S3, launched last May, sold more than 40 million in seven months.


The new Galaxy S IV is widely expected to be released within months, and may have an unbreakable screen, full high-definition quality resolution boasting 440 pixels per inch, and a more powerful processor.


Samsung has overtaken Apple, helped in part by the popularity of its Galaxy Note II phone-cum-tablet, reinforcing the benefits of offering a wider range of handheld devices at most price points, while Apple rolled out just a single new smartphone last year globally, analysts have said.


Samsung is expected to increase its smartphone sales by more than a third this year, and widen its lead over Apple, according to researcher Strategy Analytics, which has forecast Samsung will sell 290 million smartphones in 2013 versus iPhone sales of 180 million.


Kim Sung-in, an analyst at Kiwoom Securities in Seoul, sees Samsung shipping 320 million smartphones this year and doubling sales of its tablets to 32 million.


Japan Display's plant in Nomi, southwest Japan, where Apple has invested heavily, is expected to temporarily reduce output by up to 80 percent from October-December levels, the Nikkei reported, while Sharp's dedicated facility for iPhone 5 LCD panels will trim production in January-February by about 40 percent.


(Reporting by Tokyo bureau, Avik Das and Sayantani Ghosh in Bangalore and Clare Jim in Taipei; Editing by Ian Geoghegan, Supriya Kurane)



Read More..

Coroner releases new report on Natalie Wood death


LOS ANGELES (AP) — A newly released report shows coroner's officials amended Natalie Wood's death certificate based on unanswered questions about bruises on her upper body but were lacking several pieces of evidence and could only conclude that she drowned under undetermined circumstances more than 30 years ago.


Los Angeles County coroner's officials state in an 10-page addendum to Wood's autopsy report that some of the bruises may have occurred before she went into the water and drowned, but that could not be definitively determined.


The report reveals new details about a renewed investigative interest in Wood's case, but it does not answer many of lingering questions about the actress' death and a Sheriff's Department spokesman said it has not changed the ongoing status of the case.


Officials reviewed Wood's case after sheriff's investigators in late 2011 renewed their inquiry into her November 1981 drowning. Wood's death certificate was amended last year to change her cause of death from drowning to "drowning and other undetermined factors" and the report released Monday details the reasons for the alteration.


The certificate was also amended to state that the circumstances of how the Oscar-nominated actress ended up in the water were "not clearly established."


Wood was on a yacht off Catalina Island with husband Robert Wagner and co-star Christopher Walken on Thanksgiving weekend in 1981 before somehow ending up in the water. A dinghy that was attached to the boat was found along the island's shoreline, but investigators could not locate it to review it last year.


Several of the original coroner's investigators who worked on the case were re-interviewed, and officials attempted to test some items taken during the investigation into Wood's death and an autopsy, but they could not be located.


Wood's autopsy found bruises on both of her arms, a small scratch on her neck and abrasions described as superficial on her forehead, left brow and cheek.


"The location of the bruises, the multiplicity of the bruises, lack of head trauma, or facial bruising support bruising having occurred prior to entry in the water," the report states. "Since there are unanswered questions and limited additional evidence available for evaluation, it is opined by this Medical Examiner that the manner of death should be left as undetermined," Chief Medical Examiner Dr. Lakshmanan Sathyavagiswaran wrote in the report completed in June.


Officials also considered that Wood wasn't wearing a life jacket and had no history of suicide and didn't leave a note in amending its report and Wood's death certificate.


The report was released Monday after sheriff's officials released a security hold.


Sheriff's spokesman Steve Whitmore said the agency has known about the findings in the newly released autopsy report for several months and it does not change the status of the investigation, which remains open. He said Wagner is not considered a suspect in Wood's death.


Wood was nominated for three Academy Awards during her lifetime. Her death stunned the world and has remained one of Hollywood's most enduring mysteries. The original detective on the case, Wagner, Walken have all said they considered her death an accident.


Conflicting versions of what happened on the yacht shared by Wood, her actor-husband Robert Wagner and their friend, actor Christopher Walken, have contributed to the mystery of how the actress died.


The newly released report states there are conflicting statements about when the boat's occupants discovered Wood was missing. The report estimates her time of death was around midnight, and she was reported missing at 1:30 a.m.


Read More..